Anecatibin Fumarate PK and Safety Trial

A Phase 1 clinical trial evaluating Anecatibin Fumarate Capsules was registered on ClinicalTrials.gov under NCT07538973. The trial will assess pharmacokinetics and safety in subjects with impaired liver function compared to subjects with normal liver function, with lung cancer as the condition.

Pharmaceutical companies and clinical researchers conducting Phase 1 studies involving populations with hepatic impairment should ensure compliance with ClinicalTrials.gov registration requirements and relevant FDA guidance on pharmacokinetic studies in special populations.